Gapping up
In reaction to strong earnings/guidance:
- IRBT +17.6%, IRBT +17.6%, VICR +13.1%, VRAY +9.9% (appoints Scott Drake CEO and Shar Martin COO, effective immediately; announces preliminary unaudited revenue of approx. $16 mln vs $13.4 mln consensus for second quarter; reaffirms FY18 rev guidance of $80-90 mln), USNA +9.9%, TER +6.8%, ATTU +6.4%, HA +5.9%, SPN +5.3%, SC +5.2%, FCF +5%, SLM +4.3%, KN +4.1%, RHI +3.7%, CHKP +3.6%, AKR +3.4%, DTE +3.2%, CSL +3%, UCBI +2.8%, FLIR +2.6%, ROK +2.1%, SIRI +2%, EVR +1.9%, CNI +1.5%, RNR +1.5%, AMP +1.2%, WIX +1.2%, ANTM +1.1%, RES +1.1%, IPHI +0.9%, GSK +0.8%, .
Other news:
- TORC +143% (announces 'positive' topline results from its dose-ranging Phase 2b clinical trial)
- NVRO +26.6% (after plunging ~16 points in late trade on unfavorable patent ruling)
- NBRV +3% (acquires Zavante Therapeutics for upfront consideration of approximately 8.2 mln ordinary shares)
- RETA +2.3% (continued strength despite co pricing offering of 3 mln shares of common stock at $72.00 per share)
- LULU +1.2% (appoints Calvin McDonald Chief Executive Officer)
Analyst comments:
- HA +5.9% (upgraded to Buy from Hold at Deutsche Bank)
- CROX +2.3% (upgraded to Buy at Pivotal Research Group)
- PPG +1.3% (upgraded to Buy from Neutral at Goldman)
- SNAP +0.8% (upgraded to Hold from Sell at Vertical Group)